---
title: Oral Ibuprofen Versus Placebo in Treatment of Patent Ductus Arteriosus (PDA)in Preterm Infants
nct_id: NCT05493540
overall_status: COMPLETED
phase: PHASE2
sponsor: Nada Youssef
study_type: INTERVENTIONAL
primary_condition: Patent Ductus Arteriosus After Premature Birth
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05493540.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05493540"
ct_last_update_post_date: 2023-02-28
last_seen_at: "2026-05-12T06:02:36.811Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Oral Ibuprofen Versus Placebo in Treatment of Patent Ductus Arteriosus (PDA)in Preterm Infants

**Official Title:** Oral Ibuprofen Versus Placebo in Management of Patent Ductus Arteriosus in Preterm Infants: A Double Blind, Randomized Control Trial

**NCT ID:** [NCT05493540](https://clinicaltrials.gov/study/NCT05493540)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 80
- **Lead Sponsor:** Nada Youssef
- **Conditions:** Patent Ductus Arteriosus After Premature Birth, Patent Ductus Arteriosus Conservative Management
- **Start Date:** 2021-04-15
- **Completion Date:** 2022-09-01
- **CT.gov Last Update:** 2023-02-28

## Brief Summary

The management options of Patent Ductus Arteriosus are still controversial and differ between centers. Recently, conservative management has been gaining interest as the evidence of benefit from medical treatment in terms of mortality and morbidity is lacking.

This study will compare oral ibuprofen (the standard treatment) with the conservative treatment, in terms of ductal closure and morbidity and mortality at discharge in preterm neonates less than 34 weeks.

## Detailed Description

A double-blinded, randomized, placebo-control non-inferiority trial was conducted in the neonatal intensive care unit (NICU) of Ain Shams University children's hospital, Cairo, Egypt.

Informed consent was taken from the parents or legal guardians before enrolment, after fully explaining to them the nature of the study. The approval of the Research Ethics Committee at Ain Shams University was also obtained.

All preterm neonates less than 34 weeks were assessed in the first 48 hours by clinical and echocardiographic examination by a cardiologist to detect PDA and exclude any congenital heart disease.

All neonates meeting the inclusion criteria will be randomized into one of two groups:

Medical treatment group and Placebo group. Targeted neonatal Echo was repeated after 5 days of the start of medical treatment by a neonatologist or a cardiologist to assess PDA closure.

After 7 days of intervention, open-label is offered to all patients with the option of another course for patients in the medical treatment group and Rescue therapy in the Placebo group.

The short-term morbidity is documented.

Withdrawal and replacement of individual subjects:

* The attending physician can decide to withdraw a subject from the study for urgent medical reasons. If they wish, parents or caregivers can leave the study at any time for any reason.
* Infants who are withdrawn from the study will be managed according to NICU Protocols.

## Eligibility

- **Minimum age:** 1 Hour
- **Maximum age:** 7 Days
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Gestational age ≤ 34 weeks
* PDA Size \> 1.5 mm and predominantly left-to-right shunt
* One of the following:
* Signs of Pulmonary overflow: Left atrium/Aortic diameter ratio (LA/Ao), Left Ventricular End Diastolic Diameter (LVEDD).
* Signs of Systemic Hypo perfusion: Absent or Reversed diastolic flow in the aorta, celiac/mesenteric, or Anterior Cerebral Artery (ACA)/ Middle Cerebral Artery (MCA)

Exclusion Criteria:

* Chromosomal anomaly
* Congenital heart defect, other than PDA and/or patent foramen ovale
* Congenital or acquired gastrointestinal anomaly
* Previous episodes of Necrotizing enterocolitis (NEC) or intestinal perforation
* Active bleeding, especially intracranial or gastrointestinal hemorrhage
* Contraindications to the use of ibuprofen
```

## Arms

- **Medical treatment Group** (ACTIVE_COMPARATOR) — 40 preterm neonates will receive Ibuprofen oral suspension
- **Placebo Group** (PLACEBO_COMPARATOR) — 40 preterm neonates will receive oral placebo

## Interventions

- **Ibuprofen oral suspension** (DRUG) — The medical treatment group will receive oral Ibuprofen with conservative therapy in the form of fluid restriction, Positive End Expiratory Pressure (PEEP), and/or diuretics

An additional course of Ibuprofen may be offered if there is:

1. Moderate/Severe PDA on Echocardiography
2. Prolonged ventilation or Increased ventilatory setting
3. Prolonged use of inotropes or vasopressors or escalating dose

   * Another form of treatment may be offered if the patient developed side effects from Ibuprofen
- **Placebo** (DRUG) — Placebo Group will receive Oral Placebo and Conservative therapy in the form of fluid restriction, PEEP, and/or diuretics

An Open-label option might be offered if there are concerns by attending physicians over the poor patient condition that might be attributed to persistent PDA:

1. Prolonged Ventilation or Escalating Ventilatory Setting
2. Prolonged Use Of Inotropes or Vasopressors or escalation of Doses

Rescue therapy in the form of a course of oral ibuprofen may be offered:

1. After 5 days of recruitment
2. Moderate/Severe PDA on Echocardiography
3. Prolonged ventilation or Increased ventilatory setting
4. Prolonged use of inotropes or vasopressors or escalating dose - Another form of treatment may be offered if the patient developed side effects from Ibuprofen

## Primary Outcomes

- **Incidence of PDA Closure by Echocardiography** _(time frame: Hospital discharge (approximately 3 months unless death occurs first))_ — Compare the incidence of PDA closure assessed by Echocardiography during hospitalization between the two groups

## Secondary Outcomes

- **Incidence of death during hospitalization** _(time frame: Hospital discharge (approximately 3 months unless death occurs first))_
- **Incidence of Necrotizing Enterocolitis (NEC)** _(time frame: Hospital discharge (approximately 3 months unless death occurs first))_
- **Incidence of Bronchopulmonary dysplasia (BPD)** _(time frame: Hospital discharge (approximately 3 months unless death occurs first))_
- **Incidence of Sepsis** _(time frame: Hospital discharge (approximately 3 months unless death occurs first))_
- **Incidence of Intraventricular hemorrhage (IVH)** _(time frame: Hospital discharge (approximately 3 months unless death occurs first))_

## Locations (1)

- Faculty of Medicine Ain Shams University, Cairo, Egypt

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.faculty of medicine ain shams university|cairo||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05493540.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05493540*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*